Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More

4 hours ago 2

Jonathan Ponciano, The Motley Fool

Sun, May 17, 2026 astatine 1:18 PM CDT 4 min read

Cormorant Asset Management disclosed a caller presumption successful Erasca (NASDAQ:ERAS) successful its May 15, 2026, SEC filing, purchasing 5,800,000 shares successful a commercialized estimated astatine $68.55 cardinal based connected quarterly mean pricing.

What happened

According to its SEC filing dated May 15, 2026, Cormorant Asset Management initiated a caller presumption successful Erasca by acquiring 5,800,000 shares. The estimated transaction worth was $68.55 million, calculated utilizing the mean closing terms for the archetypal 4th of 2026. The quarter-end worth of the presumption reached $93.84 million, reflecting stock accumulation and changes successful Erasca’s banal price.

What other to cognize

Erasca was a caller summation and accounted for 4.71% of Cormorant's 13F reportable assets aft the quarter
Top holdings aft the filing:
- NASDAQ:PRAX: $285.30 cardinal (14.4% of AUM)
- NASDAQ:BBOT: $160.01 cardinal (8.1% of AUM)
- NASDAQ:EYPT: $106.54 cardinal (5.4% of AUM)
- NASDAQ:EWTX: $102.69 cardinal (5.2% of AUM)
- NASDAQ:ERAS: $93.84 cardinal (4.7% of AUM)
As of May 14, 2026, Erasca shares were priced astatine $10.37, up a staggering 715% implicit the anterior twelvemonth and vastly outperforming the S&P 500, which is alternatively up astir 25%.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$10.37
Market Capitalization	$3.15 billion
Net Income (TTM)	($124.5 million)
One-Year Price Change	715%

Company Snapshot

Erasca develops clinical-stage therapies targeting RAS/MAPK pathway-driven cancers, with pb candidates including ERAS-007 (oral ERK1/2 inhibitor), ERAS-601 (oral SHP2 inhibitor), and ERAS-801 (CNS-penetrant EGFR inhibitor).
The steadfast operates a biopharmaceutical concern exemplary focused connected discovering, developing, and commercializing caller oncology therapies, with aboriginal gross expected from merchandise approvals and commercialization.
It targets patients with precocious oregon metastatic coagulated tumors, non-small compartment lung cancer, colorectal cancer, acute myeloid leukemia, and recurrent glioblastoma multiforme.

Erasca, Inc. is simply a clinical-stage biotechnology institution specializing successful targeted oncology therapies for RAS/MAPK pathway-driven cancers. The institution leverages a pipeline of differentiated tiny molecule inhibitors aimed astatine precocious unmet aesculapian needs successful oncology. Its strategical absorption connected innovative cause improvement positions it to code important gaps successful crab attraction and thrust semipermanent worth upon palmy commercialization.

What this transaction means for investors

After a monolithic tally successful Erasca stock, Cormorant’s willingness to physique a astir $94 cardinal presumption suggests the money inactive sees meaningful upside tied to Erasca’s objective pipeline alternatively than conscionable momentum trading.

The institution has been moving quickly. Earlier this month, Erasca reported encouraging aboriginal information for ERAS-0015, its pan-RAS molecular glue therapy, showing promising responses successful lung and pancreatic crab patients alongside what absorption described arsenic mostly favorable information results. The institution besides announced collaborations with some Merck and Tango Therapeutics to trial operation approaches involving KEYTRUDA and different oncology assets.

Importantly for semipermanent investors, Erasca ended the 4th with astir $409 cardinal successful currency and marketable securities, which absorption says should money operations into the 2nd fractional of 2028. Of course, Erasca inactive has nary approved products and posted a quarterly nett nonaccomplishment of $183 million. But for investors comfy with biotech volatility, this filing suggests immoderate blase healthcare funds judge the institution whitethorn person a existent changeable astatine becoming a meaningful subordinate successful precision oncology.

Read Entire Article